oral glp-1 agonist approved GLP-1: A Needle-Free Solution for Weight Loss FDA just approved orforglipron (Foundayo),

The First Wave: Older GLP-1 Medications Before semaglutide stole the spotlight, several other GLP-1 agonists were used primarily for diabetes management, with modest weight loss benefits

Regalado, A

The aim of this article is to explore their clinical rationale, assess where they fit in the current guideline approach and identify which patients may derive benefit from their use

A systematic review published in the journal Drug and Alcohol Dependence provides a detailed analysis of the findings of available clinical trials that investigated the effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder

What can be done to mitigate the effects of muscle loss during GLP-1 treatment

A study published last summer by JAMA Oncology looked at GLP-1 use and 14 obesity-related cancers and found that while the weight-loss drug lowered the risk of most cancers, there was a nonsignificant increased risk of kidney cancer particularly among people younger than 65